If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Forsteo ® (teriparatide)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Forsteo Summary of Product Characteristics (SmPC)
Forsteo® (teriparatide): Patients with History of Cancer
Patients with skeletal malignancies or bone metastases should be excluded from treatment with teriparatide.
patient with a history of cancer, take into consideration the type of
previous cancer, the risk of bone metastases, and the length of time
the patient has been in remission before prescribing Forsteo.1
Information from Summary of Product Characteristics
with skeletal malignancies or bone metastases should be excluded from
treatment with teriparatide (contraindication).2
is contraindicated in patients with prior external beam or implant
radiation therapy to the skeleton.2
of Common Cancer that Metastasize to the Bone
cancers that metastasize to the bone, in decreasing order of
This is not an all-inclusive list; cancers not included in this list
may also have the potential to metastasize to the bone.
from Clinical Studies
with a history of carcinoma in the previous five years or with a
current suspicion were excluded from participating in clinical trials
with teriparatide. However, patients with excised superficial lesions
of the skin and those with a history of carcinoma in situ of the
cervix or uterus were allowed to participate.3
was no apparent increase in the incidence of cancers among all study
participants treated with teriparatide compared with placebo during